Leber Congenital Amaurosis currently does not have a cure or a treatment, but gene therapy gives the hope that this could change, sooner than later. To move the RPGRIP1 Gene Therapy Program through to IND/Clinical Trials, there is an estimated $3.9 to 4.3 million of development costs required to advance the program through toxicology studies and fund clinical manufacturing costs. YOU can make a difference today, by donating using the link below. 100% of donations will go directly to Odylia Therapeutics, and will ultimately help prevent vision loss by supporting the efforts to treat LCA6-RPGRIP1 through gene therapy.
Your donation to Odylia, a 501(c)3 nonprofit organization, is TAX DEDUCTIBLE!